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Osteoporosis is a systemic bone disease with an increasing prevalence in the elderly
population. There is conflicting opinion about whether osteoporosis affects the alveolar
bone of the jaws and whether it poses a risk to the osseointegration of dental implants.
The aim of the present study was to evaluate the effects of systemic glucocorticoid
administration on the jaw bone density of minipigs. Thirty-seven adult female minipigs
were randomly divided into two groups. Quantitative computed tomography (QCT) was
used to assess bone mineral density BMD of the lumbar spine as well as the mandible
and maxilla, and blood was drawn. One group of minipigs initially received 1.0mg
prednisolone per kg body weight daily for 2 months. The dose was tapered to 0.5mg
per kg body weight per day thereafter. The animals in the other group served as controls
and received placebo. QCT and blood analysis were repeated after 6 and 9 months.
BMD was compared between the two groups by measuring Hounsfield units, and serum
levels of several bone metabolic markers were also assessed. A decrease in BMD was
observed in the jaws from baseline to 9 months. This was more pronounced in the
prednisolone group. Statistically significant differences were reached for the mandible
(p < 0.001) and the maxilla (p < 0.001). The administration of glucocorticoids reduced
the BMD in the jaws of minipigs. The described model shows promise in the evaluation
of osseointegration of dental implants in bone that is compromised by osteoporosis.
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INTRODUCTION
Osteoporosis is a systemic disease that affects bone mass and
architecture, increasing the risk of bone fractures (Rachner et al.,
2011). Osteoporosis is prevalent in the United States, Europe,
and Japan, causing over 4.5 million fractures annually (WHO
Scientific Group on the Assessment of Osteoporosis at Primary
Health Care Level, 2004). As consequence of an aging population,
an increasing number of people suffer from osteoporosis.
The most common form of osteoporosis is post-menopausal
osteoporosis in females, due to reduced estrogen levels. Other risk
factors for the development of osteoporosis include patient age
and long-term systemic exposure to exogenous glucocorticoids.
The clinical diagnosis of osteoporosis is usually confirmed
radiographically, via dual-energy X-ray absorptiometry (DXA)-
based bone densitometry (Felsenberg and Gowin, 1999) and,
more recently, with high resolution quantitative computed
tomography (hrQCT; Snedeker et al., 2006; Graeff et al., 2013).
The influence of both local and systemic diseases on the
osseointegration of dental implants has been a repeated point
of discussion. For example, it has been shown that periodontitis
in conjunction with smoking (Heitz-Mayfield and Huynh-Ba,
2009), and radiotherapy prior to implant placement (Chambrone
et al., 2013), negatively affect implant integration. With regard
to osteoporosis, there are contradictory reports on the success
rates of dental implants placed in osteoporotic bone. Whereas,
some studies describe no influence of osteoporosis on the implant
osseointegration (Dvorak et al., 2011a), other authors report
higher loss rates of implants in osteoporotic bone (Moy et al.,
2005; Alsaadi et al., 2008). It is uncertain whether osteoporosis
commonly induces areas of rarefaction in the alveolar processes
of the jaws that are of clinical relevance to implant success.
While some authors report that osteoporotic skeletal changes
are reflected in alveolar bone changes (Jonasson et al., 2006),
others have found no correlation between the condition of the
general skeletal and alveolar bone structures (Kingsmill and
Boyde, 1999).
Such possible correlations can be analyzed in animal models.
In osteoporosis research, rodent models have been used for
analysis of the integration of biomaterials (Stadlinger et al.,
2013). In rodent studies, ovariectomy serves to induce an
osteoporotic state. Large animal models more closely resemble
human anatomy and human patterns of wound healing, allowing
the application of regular-sized surgical instruments and dental
implants. However, due to practicalities, it has been uncommon
to employ systemically impaired large animal models for the
analysis of dental implant integration in bone or soft tissue
(Thoma et al., 2012). Sheep, minipigs, and dogs may serve for
such studies. The establishment of an osteoporotic state in large
animals is possible by various means. Usually osteoporosis is
induced by ovariectomy, however this has been reported to have
a limited influence on nulliparous pigs (Scholz-Ahrens et al.,
1996). Other approaches involve a calcium-deficient diet, the
systemic application of glucocorticoids, or a combination of
those approaches. Recently, an animal model has been reported,
showing mandibular bone loss following a hypothalamic-
pituitary disconnection (Oheim et al., 2014).
The application of glucocorticoids inminipigs has been shown
to induce reduction of BMD in the lumbar spine as assessed by
quantitative computed tomography (QCT; Scholz-Ahrens et al.,
2007). QCT enables repeatedmeasurements of the entire skeleton
over time and is therefore suitable for large animal studies on
bone structure.
In most pre-clinical studies, implant integration is analyzed
in pristine bone under unimpaired osseous conditions. The aim
of this minipig study was to establish a large animal model with
glucocorticoid-induced osteoporosis, for the analysis of implant
osseointegration under impaired systemic osseous conditions. To
achieve this effect, the experimental animals received systemic
glucocorticoid therapy for 9 months. During this period, the
animals underwent three QCT assessments. The hypothesis was
that glucocorticoid application for 9 months would induce a
significant decrease of BMD in both the lumbar spine and the
alveolar bone of the jaws.
MATERIALS AND METHODS
Experimental Design
The study protocol was approved by the Commission for
Animal Studies at the District Government, Dresden, Germany
(file reference: 24-9168.11-1/2008-43). The study was conducted
in accordance to the recommendations and guidelines of the
Commission for Animal Studies at the District Government,
Dresden, Germany.
For the study, 37 adult female miniature pigs (nulliparous,
aged 18–20 months, average weight 72.5 ± 16.7 kg) of the
breed Mini-Lewe were used. The animals were randomly divided
into two groups: Group I (29 animals) received daily oral
prednisolone, 1mg per kg body weight in the initial phase.
After 2 months, the dosage was reduced to 0.5mg prednisolone
per kg body weight per day. Prednisolone administration was
performed according to the protocol described by Scholz-Ahrens
(Scholz-Ahrens et al., 2007). Group II (eight animals), which
received neither prednisolone nor a carrier, served as control.
Before the commencement of prednisolone, and at the 6- and
9-month time-points of prednisolone administration, QCT was
performed for each animal, and blood samples for laboratory
assessment and measurement of biochemical markers of bone
turnover were also taken.
Nutrition
Prior to the start of the study, the animals were fed a diet
consisting of pollard, wheat bran, and corn silage obtained
from a local food producer. The pollard contained 0.57% of
calcium and 0.55% of phosphorus. The content of vitamin D3
was 328 international units (IU) per kg. After initiation of the
glucocorticoid therapy, the experimental animals were fed a
calcium-deficient diet omitting the pollard. The diet contained
58.3% wheat bran and 41.7% corn-based silage. The wheat bran
contained 0.07% calcium and 0.05% phosphorus. The content
of vitamin D3 was <300 IU per kg. The diet of the control
group remained unchanged. Water was available ad libitum. The
components of the animal nutrition were analyzed prior to the
study (LUFA-ITL GmbH, Kiel, Germany).
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Sedation
Computed tomography investigations and the collection of
the blood samples were performed under sedation, under the
surveillance of a veterinarian. The medication for sedation
involved a mixture of 1 mg/kg body weight midazolam
(Ratiopharm GmbH, Ulm, Germany), 10mg/kg body weight
ketamine (Riemser Arzneimittel AG, Greifswald, Germany),
and 0.05mg/kg body weight atropine (Eifelfango Chem.-Pharm.
Werke, Bad Neuenahr-Ahrweiler, Germany), administered
intramuscularly.
Quantitative Computed Tomography
The computed tomography scanner was a multislice-CT
(SOMATOM 16, Siemens Healthcare, Erlangen, Germany). The
minipigs were positioned ventrally due to veterinary aspects of
respiration, with mandible and maxilla parallel to the horizontal
plane. The images were acquired by applying the spiral technique
with a collimation of 16 × 0.75 mm. The data acquisition was
performed axial using a slice-thickness of 0.75mm. The field of
view was chosen 265 × 265mm for the jaw scan and 200 ×
200mm for the scan of the lumbar vertebrae with a matrix of 512
× 512. Thus, a pixel spacing of 0.426× 0.426mm for the jaw scan
and of 0.445× 0.445mm resulted. The optimal set-up conditions
for the jaw scan were a tube voltage of 120 kV and 36mAs. For the
vertebra region the same tube voltage was used with 274mAs.
The data was acquired by a filtered back projection with
convolution kernel H60s for the jaw scan and B70s for the
vertebra scan. Saving was performed as digital imaging and
communication in medicine (DICOM) standard using the
Leonardo workstation (LEONARDO VD10B; Syngo VX49B;
Siemens Healthcare Diagnostics GmbH, Eschborn, Germany).
The analyses and measurements of the CT scans were
performed with interactive data language software (IDL 7.0.0,
ITT-Visual Information Solutions, Boulder/CO, USA) by two
experienced examiners (JK, SE). To calculate the inter- and
intra-observer reproducibility, measurements of eight randomly
selected animals were repeated twice by each examiner with
a time interval of 2 weeks. Calibration was performed using
a reference phantom containing a bone-like and a water-like
phase (Osteo Phantom, Siemens Healthcare, Erlangen, Germany)
placed parallelly to the horizontal plane. A gray scale of
Hounsfield units (HU) served for the analysis of the bonemineral
density. A threshold was defined in order to ensure that no soft
tissue (e.g., fat) or dental structures (e.g., roots) were included
in the measurements. In preliminary tests, a mean density of the
mandibular and maxillary cortical bone of 1386 HU was assessed
(data not shown). Furthermore, the gray values of the soft tissues
in the bone marrow were measured to have a peak value below
0 HU. According to the resulting histograms, the thresholds at 0
HU for the minimum and at 1,350 HU for the maximum were
defined. As mineralized dental structures show comparable or
higher density values than cortical bone they could be precluded
from the measurements by the threshold, likewise.
For the radiographic analysis of the jaw region, the
radiographs were positioned parallelly to the transversal plane.
The vertical position of the transversal cutting plane was
determined by the root tips of the three premolar teeth in each
jaw. The regions of interest in the mandible and maxilla were
defined as follows: The oral and buccal borders were defined
by the inner layer of the cortical bone. The distal edge of the
canine root served as the anterior border and the mesial root
of the third molar as the distal border. The matching of the
radiographs of the baseline QCT and of the QCTs after 6 and
9 months was achieved by using constant anatomical structures
e.g., pterygoid process, the bony nasal septum and the tuber
maxilla in the upper jaw. In the mandible, the profile of the oral
and vestibular cortical bone was used for the matching of the
images. For the measurement of the BMD in lumbar vertebrae
I–III, the radiographs were positioned parallel to the axial plane.
The region of interest was defined through the ventral cortical
bone and the cortical bone of the spinal canal. The lateral border
was defined by a dense trabecula connecting the ventral cortical
bone and the spinal canal in dorsomedial direction. The regions
of interest are depicted in Figures 1, 2 for the jaw region and
in Figure 3 for the vertebral region. For the measurement of the
bone density, the gray values of the pixels in the regions of interest
were assessed and displayed in Hounsfield Units using the IDL-
software. The mean value and standard deviation of each region
of interest was calculated. In the upper and lower jaw, the left and
right side were measured separately, and were later pooled for the
statistical evaluation.
FIGURE 1 | The region of interest for the analysis of the computed
tomography scans is depicted in the maxilla. The area is extended between
the distal edge of the canine root and the mesial edge of the third molar.
Laterally, the cortical bone served as border.
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FIGURE 2 | The region of interest for the analysis of the computed
tomography scans is depicted in the mandible. The area is extended between
the distal edge of the canine root and the mesial edge of the third molar.
Laterally, the cortical bone served as border.
FIGURE 3 | In the vertebrae, the region of interest was defined as a polygon
being limited by the ventral and dorsal cortical bone and dorso-laterally by a
dense trabecula between the ventral cortical bone and the spinal canal.
Serum Parameters
Blood samples were taken before the commencement of
glucocorticoid administration and after 6 and 9 months,
respectively. The samples were always obtained from the
ear vein at the same time of the day using serum gel
monovettes (Sarstedt AG & Co., Nürmbrecht, Germany)
and stored at 4◦C until centrifugation. Subsequently, the
following parameters were analyzed using an automatic test
system (cobas c, Roche Diagnostics, Mannheim, Germany).
The serum level of ionic calcium and ionic phosphorus
were analyzed by photometric test kits (CA2 and PHOS2).
The level of total alkaline phosphatase was measured by an
extinction test kit (ALP2). For the analysis of the levels
of beta crosslaps an immunoassay test kit (ECLIA) was
used. All test kits were obtained from Roche Diagnostics,
Mannheim, Germany. Bone specific alkaline phosphatase was
measured using an immunoassay (MicroVueTM BAP, Quidel
Corporation, San Diego, CA, USA). The serum level of
25(OH) Vitamin D was analyzed by a chemiluminescence
assay (LIAISON R© 25 OH Vitamin D TOTAL Assay). The
analysis of the osteocalcin level was performed using a two-
site immunoradiometric assay (CA 72-4 IRMA). Both assays
were obtained from DiaSorin Inc., Stillwater, MN, USA.
Osteoprotegrin (OPG) levels were analyzed by an enzyme-
linked immune sorbent assay (Osteoprotegrin ELISA kit,
Immundiagnostik AG, Bensheim, Germany). The serum level of
1,25(OH)2-Vitamin D was measured using a radioimmunoassay
(1,25-Dihydroxy Vitamin D RIA, Immunodiagnostic Systems
GmbH, Frankfurt am Main, Germany). All analyses were
performed by the Institute for Clinical Chemistry and Laboratory
Medicine (Medical Faculty “Carl Gustav Carus,” Technische
Universität Dresden, Dresden, Germany) using standardized
laboratory methods.
Statistical Analysis
The degree of agreement between the two observers and the
degree of agreement between the two measurements were
assessed by a reliability analysis. The inter- and intra-observer
reliability is described by the intraclass correlation coefficient
(ICC) taking a two-way random model with absolute agreement
definition. The animal experiment was planned and carried
out as longitudinal study. Consequentially the analyses were
done by ANOVA using linear mixed models. The models
included fixed effects associated with treatment, time, and
the interaction between treatment and time. The residual
covariance matrix was specified as a heterogeneous compound
symmetry (CSH), so that the variances differ across the levels
of time. Estimated means and their 95%-confidence limits
are given. Post-hoc tests and confidence limits are alpha-
adjusted using the Tukey–Kramer method. The statistical
analysis was performed using SPSS 19 (SPSS Inc., Chicago,
Illinois, USA) and SAS 9.3 (SAS Institute Inc., Cary, NC,
USA).
RESULTS
From the initially 37 minipigs, two animals of the prednisolone
group died due to unknown cause and were excluded from the
analysis. Thus, 35 animals completed the study period and could
be included in the evaluation.
Quantitative Computed Tomography
Intra- and Inter-Observer Control
The intra-observer analysis showed an ICC of 0.992 (95%-
confidence interval: 0.987–0.995) for observer I and an ICC of
0.991 (95%-confidence interval: 0.987–0.994) for observer II. The
inter-observer analysis showed an ICC of 0.992 (95%-confidence
interval: 0.988–0.995) for the first time point and an ICC of
0.990 (95%-confidence interval: 0.984–0.993) for the second time
point. A statistically significant difference between both observers
could not be found, neither for the first (p = 0.592) nor for the
second time point (p= 0.224).
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Control Group—Development of Bone Mass with
Aging
With regard to BMD-values, the control group showed a
general decrease from baseline to the 6-month examination. This
decrease was statistically significant for all regions of interest.
From 6 to 9 months, a statistically significant increase of BMD
was obvious for all examined regions. When comparing the
baseline values to those obtained after 9 months, an overall
decrease of BMD was found. However, this decrease was
only statistically significant for the maxilla. For vertebrae and
mandible no significant changes could be found (vertebrae: p =
0.988; mandible: p= 0.995).
Effects of Glucocorticoid Exposure on Bone Mass
At the baseline point of the study, the values for BMD
in the lumbar vertebrae and the maxilla differed statistically
significantly between control and treatment group. For the
mandible, no statistically significant difference could be observed
(p= 0.973). In the computed tomography results after 6 months,
the BMD showed a decrease in all evaluated regions. This
decrease was statistically significant for both the control and
the glucocorticoid group. Between the groups, no statistically
significant differences could be found for any region. After 9
months, an increase of BMD in the control group was obvious
for all evaluated regions compared to the 6-month values. This
increase was statistically significant for all regions. However,
the values after 9 months did not reach the baseline level
again. Compared to baseline values, the decrease was statistically
significant for the maxilla (p < 0.001). For the lumbar vertebrae
and the mandible, the differences were not statistically significant
(lumbar vertebrae: p = 0.981; mandible: p = 0.559). An example
for the rarefied trabecular structure in the jaw bone is given
in Figures 4A,B for the maxilla and in Figures 5A,B for the
mandible.
FIGURE 4 | Trabecular rarefication over time shown in the maxilla. Compared
to the baseline (A) the spongious area in the region of interest appears in
darker gray values after 9 months (B) indicating a loss of mineralization.
After 9 months, there was an increase in the bone density
values in the lumbar vertebrae in the glucocorticoid group
compared to the 6-month value. This was statistically significant.
In the jaw region, a slight decrease of BMD was observed.
However, this decrease did not reach statistical significance when
compared to the values after 6 months (maxilla: p = 0.551;
mandible: p = 0.559). Compared to the baseline, the values
after 9 months of glucocorticoid administration were lower. For
the lumbar vertebrae region, this difference was not statistically
significant (p = 0.981). In the jaw region, the difference reached
statistical significance. When compared to the control group the
values for BMD differed statistically significant for all examined
regions in the glucocorticoid group. The detailed chronological
data and statistical significant differences are shown in Table 1.
Serum Parameters
Control Group
In the control group, the level of ionic phosphorus decreased
slightly during the period of study while values of ionic calcium,
alkaline phosphatase, osteocalcin, and 1,25(OH)2-vitamin D
varied. The values of bone specific alkaline phosphatase and beta
crosslaps increased. During the study period, an increase could
be observed for OPG serum levels. The means and their standard
deviations are shown in Table 2. Statistical significant differences
are depicted in Figure 6.
Effects of Glucocorticoid Exposure on Serum
Parameters
The serum values for ionic phosphorus showed a decrease
over the study period. Ionic calcium values varied over the
study period as in the control group. From the baseline to
FIGURE 5 | Trabecular rarefication over time shown in the mandible.
Compared to the baseline (A) the spongious area in the region of interest
appears in darker gray values after 9 months (B) indicating a loss of
mineralization.
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TABLE 1 | Values of bone mineral density in Hounsfield Unit (HU).
Region of interest Baseline (HU) 6 months (HU) 9 months (HU)
Control Mean ± SD Mean ± SD Mean ± SD
Lumbal vertebrae 464.70*1 ± 46.44 382.71*+3 ± 40.90 444.67+3,10 ± 43.29
Maxilla 569.21**$2,6 ± 66.24 407.25**#4 ± 72.87 474.80#$4,6,11 ± 76.36
Mandible 613.41
′′
± 74.99 537.14
′′∧5 ± 87.46 598.83∧5,12 ± 112.85
GLUCOCORTICOID
Lumbal vertebrae 377.801 ± 51.49 339.877 ± 57.84 366.377,10 ± 71.76
Maxilla 421.912,8 ± 119.20 323.25 ± 69.74 315.518,11 ± 71.23
Mandible 541.239 ± 151.83 424.40 ± 106.84 402.899,12 ± 99.23
Means and standard deviations (SD) are depicted. The statistical significant differences of the pairwise comparisons are marked (*, **, +, $, 2, 3, 6, 8, 9, 11, 12: p < 0.001;”, #, ∧, 1, 4,
5, 7, 10: p < 0.05).
TABLE 2 | The development of serum parameters over the study period.
CT 1 CT 2 CT 3
Parameter Group Mean SD 95% CI Mean SD 95% CI Mean SD 95% CI
PO2−4 /mmol*l
−1 Control 2.008 0.541 (1.752, 2.263) 1.943 0.188 (1.789, 2.096) 1.950 0.148 (1.712, 2.188)
Glucocorticoid 2.253 0.285 (2.114, 2.392) 1.716 0.220 (1.633, 1.800) 1.708 0.365 (1.578, 1.838)
Ca2+/mmol*l−1 Control 2.266 0.440 (1.981, 2.552) 2.396 0.086 (2.115, 2.678) 1.368 0.381 (1.095, 1.640)
Glucocorticoid 2.027 0.385 (1.872, 2.183) 1.993 0.439 (1.840, 2.147) 2.128 0.378 (1.979, 2.276)
AP/µmol*l−1 Control 0.754 0.161 (–0.178, 1.686) 0.776 0.222 (0.459, 1.093) 0.744 0.126 (0.476, 1.012)
Glucocorticoid 1.678 1.457 (1.171, 2.185) 0.734 0.483 (0.561, 0.907) 0.807 0.415 (0.661, 0.953)
BAP/U*l−1 Control 16.738 4.194 (−24.081, 57.556) 29.588 5.192 (16.734, 42.441) 27.750 2.799 (15.887, 39.613)
Glucocorticoid 71.830 63.894 (49.611, 94.048) 23.793 19.950 (16.796, 30.789) 25.330 18.523 (18.872, 31.787)
β-Crosslaps/ng*ml−1 Control 0.385 0.099 (0.244, 0.526) 0.736 0.172 (0.426, 1.047) 0.731 0.081 (0.499, 0.963)
Glucocorticoid 0.838 0.215 (0.761, 0.915) 0.499 0.478 (0.330, 0.668) 0.600 0.361 (0.474, 0.726)
Osteocalcin/ng*ml−1 Control 13.125 3.605 (1.195, 25.055) 34.988 7.618 (21.428, 48.547) 19.763 8.833 (7.210, 32.315)
Glucocorticoid 121.822 18.591 (115.328, 128.316) 27.563 20.865 (20.182, 34.944) 21.137 19.118 (14.304, 27.970)
OPG/pmol*l−1 Control 0.140 0 (0.042, 0.238) 0.140 0 (−0.257, 0.537) 0.180 0.091 (0.082, 0.278)
Glucocorticoid 0.286 0.153 (0.233, 0.339) 0.540 0.622 (0.324, 0.756) 0.200 0.146 (0.147, 0.253)
1,25(OH)2D3/pg*ml
−1 Control 141.625 27.184 (118.075, 165.175) 57.463 16.318 (44.053, 70.872) 143.050 51.234 (114.620, 171.480)
Glucocorticoid 87.433 34.082 (74.614, 100.253) 48.633 19.220 (41.334, 55.932) 101.778 35.721 (86.302, 117.253)
25(OH)D3/ng*ml
−1 Control 7.638 2.744 (6.692, 8.583) 4.000 0 (3.975, 4.025) 5.488 1.750 (4.908, 6.067)
Glucocorticoid 4.315 0.407 (3.800, 4.829) 4.007 0.038 (3.994, 4.021) 4.000 0 (3.684, 4.316)
Means, their 95% confidence intervals (CI) and standard deviations (SD) are depicted.
the measurement after 6 months, alkaline phosphatase and
bone specific alkaline phosphatase decreased. After initiating
the administration of glucocorticoids, the values for osteocalcin
decreased after 6 months compared to the baseline. The serum
levels for beta-crosslaps, OPG, and 1,25(OH)2-vitamin D varied.
The detailed data is depicted in Table 2 and statistical significant
differences are depicted in Figure 6.
Inter-Group Comparison
At baseline, the values for all serum parameters differed between
the groups. A decrease could be observed for ionic phosphorus
in both groups, but was more pronounced in the glucocorticoid
group. The decrease differed statistically significant for both
time points (p = 0.008; p = 0.009). When comparing bone-
specific alkaline phosphatase, osteocalcin, and 25(OH)-vitamin
D, the development in both groups differed significantly (alkaline
phosphatase: p = 0.013; p = 0.017; osteocalcin: p < 0.001;
25(OH)-vitamin D: p < 0.001). No statistically significant
differences were found for the trends of the levels of alkaline
phosphatase (p= 0.076; p= 0.111), OPG (p= 0.266; p= 0.129).
For 1,25(OH)2-vitamin D, the development initially differed
between the groups (p= 0.006) but not for the entire study period
(p= 0.443).
DISCUSSION
The osseointegration of dental implants is commonly analyzed
in animal models prior to clinical application in humans. In
treatment clinics however, the situation is often different to
ideal pre-clinical laboratory conditions. Many patients suffer
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FIGURE 6 | Serum parameters during the study period: (A) inorganic phosphorus; (B) calcium; (C) alkaline phosphatase; (D) bone specific alkaline phosphatase
(BAP); (E) β-crosslaps; (F) osteocalcin; (G) osteoprotegrin; (H) 1,25-dihydroxyvitamin D; (I) 25(OH)-hydroxyvitamin D. Statistical significant differences within the
groups over the study period are marked (*, **, #, +).
from local bone defects due to bone resorption following tooth
extraction or as a consequence of local trauma and require bone
augmentation prior to implant therapy. Further, an increasing
number of patients suffer from systemic diseases such as diabetes
mellitus or osteoporosis, and are receiving medical therapy.
These factors might interfere with bone healing, osseointegration
of implants, and the health of oral soft tissues (Sachelarie et al.,
2016).
Bone Mineral Density
In the present study, BMD was measured using QCT, which is
frequently used in animal studies (Scholz-Ahrens et al., 2007;
Veigel et al., 2011). The measurements are focused on the
trabecular bonemineral density, as glucocorticoid administration
seems to have an important effect (Wetzsteon et al., 2009;
Paggiosi et al., 2015). Furthermore, the gray values of the cortical
bone and the dental structures are in the same range. Thus,
cortical bone has usually been excluded from the measurements
to avoid a biased analysis through inclusion of dental structures
(roots). Scholz-Ahrens et al. found a statistically significant
decrease in BMD in lumbar vertebrae after 8 months of
glucocorticoid treatment (Scholz-Ahrens et al., 2007). This
partially agrees with the results of this current study, which
showed a statistically significant decrease in lumbar vertebrae
after 6 months with a slight increase of BMD after 9 months.
This might be related to an increase of body weight which is
described for minipigs after completed adolescence (Richel and
Waldmann, 2015). The growing weight might be a stimulus
for bone formation in the vertebral region due to an increase
of stress. An unexpected finding in the current study were the
statistically significant differences considering the baseline values
of bone mineral density. One possible reason for the different
baseline data might be inter-animal variance. All came from
the same herd, however, showed a variance in age and weight.
Another reasonmight be the different group size (8 vs. 27 animals
completing the study). If the control group would have had an
equal group size to the glucocorticoid group, the differences
might have been lower due to the compensation of extremal
values.
The results for maxillofacial BMD in animals undergoing
the induction of osteoporosis are different to those of lumbar
bone. In a study using ovariectomized sheep, a pronounced
horizontal and vertical bone loss in the mandible was described
after 3 and 12 months (Johnson et al., 1997). However, a metric
measurement of bone volume was not performed. Using the
same animal model, another study measured BMD 12 months
after ovariectomy, and showed no changes in the region of
the diastema or the mandibular ramus (Johnson et al., 2002).
Bone density in the alveolar regions however was significantly
decreased, by 27.8%. This is in accordance with our results, which
showed a progressive rarefication of the trabecular structure of
the maxilla and the mandible. This rarefication of trabecular
bone was found to be more pronounced in mandibular bone.
In the experimental group, both a progressive decrease over
time and a decrease in comparison to the control group were
recorded.
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Animal Models
The consideration of bone quality raises the question of
appropriate animal models to simulate human osteoporosis.
Osteoporotic large animal models have been established in sheep,
dog, and pigs (Volozhin et al., 1990; Scholz-Ahrens et al., 2007;
Dvorak et al., 2011b; Zhang et al., 2014; Kielbowicz et al., 2015).
The most frequently described large animal model seems to be
the sheep (Dvorak et al., 2011b; Veigel et al., 2011; Kielbowicz
et al., 2015). With regard to the oral and maxillofacial situation,
the minipig seems to be the most suitable model. First, it is an
omnivore, so the diet has more similarities to a human diet than
do sheep and dog models. Furthermore, the bone and oral tissues
structure as well as bone turnover is quite similar to humans
(Hönig and Merten, 1993; Hönig et al., 1997; Wang et al., 2007;
Swindle et al., 2012). In a review, Pearce et al. concluded that
both bone composition and bone remodeling in pigs are largely
similar to that of humans, while micro- and macrostructure
can be considered as moderately similar (Pearce et al., 2007).
Regarding the age, the minipigs included in the current study
can be considered as young adults. The life span of the breed
Mini-Lewe was described with 10–15 years (Leucht et al., 1982).
Richel observed in a longitudinal study of 144 Mini-Lewe pigs
no further increase in the withers height and crown rump length
after an average age of 20 months. Day 600 post-partum was
defined as the time point of completed adolescence (Richel and
Waldmann, 2015). This is in accordance with the findings of
the current study, as no bone growth could be determined when
comparing the matched images of the CT scans during the study
period. Unlike in humans, in non-primate mammals there is no
description of a physiological menopause state in the literature
(Finn, 2001). Therefore, the use of young adult minipigs seems
to be appropriate as there is no change in estrous cycle expected
with increasing age. Additionally, when implant osseointegration
is evaluated, the anatomy of the jaw of minipigs allows the
application of the same instruments as used for human patients
(Stadlinger et al., 2012).
Serum Parameters
Any systemic animal model needs to be validated by systemic
parameters. Along with the measurement of bone density, the
analysis of serum parameters is of particular interest, providing
better understanding of bone metabolism.
Inorganic Phosphorus
The values of the inorganic phosphorus decreased in both groups
which was more pronounced in the glucocorticoid group. When
comparing the current values to the literature the values of the
control group were in the same range (2.38 ± 0.86 to 3.10 ±
0.65mmol∗l−1; Mieth, 1978; Leucht et al., 1982; Gusewski, 1983;
Richel and Waldmann, 2015). Increasing age was discussed as
a possible reason for this decrease by Gregor et al. but could
not be confirmed in other evaluations (Gregor, 1979; Richel
and Waldmann, 2015). In a recent study, inorganic phosphorus
values between 1.55 and 2.24 mmol∗l−1 were measured in female
Aachen minipigs, a breed descending from the Mini-Lewe strain
(Pawlowsky et al., 2017). However, these differences might be due
to a different state of growths as the used animals were aged 6
months. When comparing both groups during the study, lower
phosphorus levels were obvious in the glucocorticoid group. This
state might be considered as hypophosphatemia which possibly is
caused by the reduced intake of vitamin D3 of the glucocorticoid
group. Furthermore, hypophosphatemia could be corresponding
with lower levels of 1,25(OH)2-vitamin D3 in the glucocorticoid
group what could be observed in the present study. One possible
reason for the lower phosphorus values might be an interaction
of glucocorticoids and the phosphate balance (Levi et al., 1995).
Calcium
The values of serum calcium varied over the study period in
both groups ranging from 1.368 to 2.396 mmol∗l−1. Values
<2.1mmol∗l−1 in humans are considered as hypocalcemia
(Fong and Khan, 2012). In the literature, values between 3.1
and 2.5mmol∗l−1 are stated (Mieth, 1978; Leucht et al., 1982;
Gusewski, 1983; Richel and Waldmann, 2015). Symptoms of
acute decreased serum calcium levels include muscle spasms,
heart failure, and neuromuscular irritability whereas a slow
decrease of calcium levels might remain without symptoms
(Fong and Khan, 2012). As no of the animals in the present study
developed comprehensibly any of these symptoms it is unlikely
that there was an apparent hypocalcemia.
Alkaline Phosphatase and Bone-Specific Alkaline
Phosphatase
The values of total alkaline phosphatase and bone-specific
alkaline phosphatase showed a significant decrease after
glucocorticoid administration for 6 months. These findings were
consistent with those of Ikeda et al., who observed a reduction
of bone-specific alkaline phosphatase and osteocalcin values
in serum of adolescent miniature pigs under glucocorticoid
treatment (Ikeda et al., 2003). This might be explained
by decreased bone formation due to supressed osteoblast
activity (Lukert et al., 1986; Prummel et al., 1991). Clinically,
a statistically significant correlation between bone alkaline
phosphatase as well as osteocalcin levels and the age was found
in postmenopausal women (Lumachi et al., 2009). However, a
correlation between these bone markers and the BMD was not
observed.
β-Crosslaps
The C-terminal telopeptide of the type I-collagen is termed
as β-Crosslaps. It is considered as bone resorption marker
(Okabe et al., 2004). In a clinical study, the changes of β-
Crosslaps in serum correlated with the annual changes in BMD
in postmenopausal women (Christgau et al., 1998). They are of
crucial value to monitor the effect of antiresorptive therapies
(Christgau et al., 1998). Furthermore, an increased level of β-
Crosslaps and OPG was observed in patients suffering from
Wilsons disease and osteoporosis (Hegedus et al., 2002). No such
results could be observed in the present study. A reason might
be a wide interindividual variety of the serum levels. However,
there is little literature describing the levels of β-Crosslaps in
pigs.
Osteocalcin
The osteocalcin serum levels in the glucocorticoid group
decreased significantly after 6 months of prednisolone
administrations. This was not observed in the control group.
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In human studies, osteocalcin was described as a sensitive
marker for osteoblastic depression under glucocorticoid therapy
(Lukert et al., 1986; Ekenstam et al., 1988). The effects were
pronounced when doses of glucocorticoids between 5 and 30mg
were administered daily over a period of at least 3 months
(Lukert et al., 1986). In our study, a daily average dosage
correlating to 35–45mg prednisolone in human subjects (based
on body weight) over a period of more than 4 months was
assumed. This implies a comparable effect on the osteocalcin
level (Scholz-Ahrens et al., 2007). However, the baseline values
of both groups differed significantly, limiting this comparison.
One possible reason for low values of osteocalcin might have
been the degradation of osteocalcin by proteases of erythrocytes
and leukocytes. In cases of difficult blood drawing degradation
might have started already before further processing of the blood
samples.
OPG
OPG is a glycoprotein that regulates bone density (Yano et al.,
1999). A significant correlation was found between OPG serum
level and age (Yano et al., 1999; Fahrleitner-Pammer et al., 2003).
There was no such finding in the present study. Possibly, the
age range of the minipigs was too small for the observation
of such an effect. In contrast to our study, where young adult
animals were examined the mentioned study evaluated patients
with an age ranging from young adults to elderly patients.
Furthermore, there is an increased level of OPG in patients
suffering from osteoporosis (Yano et al., 1999). In the present
study, slightly increased levels of OPG were observed in the
glucocorticoid group during the study period. This, however,
showed no significant statistical difference when compared to
the control group. In a study of ovariectomized rats, a transient
increase of OPG was found in the initial stage of osteoporosis,
which might correlate with the increase of OPG observed in our
study (Miyazaki et al., 2004).
1,25-Dihydroxyvitamin D and 25(OH)-Hydroxyvitamin
D
The levels measured for 1,25-dihydroxyvitamin D were variable
over the study period in both groups. This is in accordance
to the literature, where increases, decreases, and an absence of
alterations of the 1,25-dihydroxyvitamin D levels in individuals
undergoing glucocorticoid therapy are described (Hodsman
et al., 1991; Prummel et al., 1991; van der Veen and Bijlsma,
1992). However, in contrast to our study, higher glucocorticoid
doses given intravenously cause a pronounced decrease (van der
Veen and Bijlsma, 1992). To minimize extraneous influences,
animals were housed in a stable and both groups received
an equally vitamin D3 deprived (<300 IU/kg) daily diet.
Comparable to other studies, no strong correlation could be
found between the changes in bone metabolism and serum levels
of 1,25-dihydroxyvitamin D (Seeman et al., 1980).
In summary, the serum parameters in the current study
showed a wide range of values. In comparison to the literature,
there are concordances but also some discrepancies. One
potential reason is the fact, that different breeds of minipigs
are being compared. Furthermore, in contrast to humans, there
are no standard values for most parameters in minipigs. For
some parameters, there were no reference values of pigs available
at all. Thus, only a comparison to values obtained from other
species was possible. Here, further studies are needed to elucidate
potential correlations. Another possible reason might be the use
of different analytical methods (Richel and Waldmann, 2015).
Methods of Osteoporosis Induction
The induction of an osteoporotic state in large animal models
has been described by means of ovariectomy, calcium-deficient
diet, glucocorticoid administration, and combinations of these
approaches (Scholz-Ahrens et al., 1996, 2007; Kielbowicz et al.,
2015). In comparison to deficient nutrition and glucocorticoid
application, ovariectomy carries the disadvantage of a surgical
intervention, which is a cause of stress for the animals.
Furthermore, the effect of ovariectomy on nulliparous animals
has been reported to be limited (Scholz-Ahrens et al., 1996). This
would apply to the animals in the current study. Additionally,
ovariectomy creates a sudden change in the hormonal balance,
which is not entirely comparable to the postmenopausal
situation, where the hormone levels change more gradually. In
distinction, the administration of glucocorticoids over a period
of time might lead to a gradual induction of osteoporosis, more
closely mimicking the natural disease condition. However, a
longer period of glucocorticoid administration may be required
to show measurable effects on bone density. One limitation of
this study might be the unequal size of the animal groups. This
might cause some bias in the statistical evaluation e.g., statistically
significant differences in BMD at the baseline. The reason was
to minimize the total number of animals used. This was similar
to other studies, where unequal group sizes for treatment and
control groups have also been used (Scholz-Ahrens et al., 2007;
Kielbowicz et al., 2015).
Compared to intramuscular application of glucocorticoids
one limitation of oral administration is the fact that the
individual animal dose is not fully calculable, because of
the uncertainty about complete ingestion and absorption.
Furthermore, glucocorticoids have various metabolic effects not
limited to the stimulation of bone resorption and induction of
osteoblast apoptosis (Dalle et al., 2001; Spreafico et al., 2008).
Regarding the suitability as a model for dental implant research,
glucocorticoid administration might lead to delayed wound
healing. Morin and Fardet described altered wound healing in
a retrospective study in humans, when glucocorticoids were
taken for more than 6 months (Morin and Fardet, 2015). Dental
implant clinics are seeing an increasing number of patients with
progressive osteoporosis secondary to the use of glucocorticoid
medications for the treatment of rheumatoid arthritis or
following organ transplantation. Thus, despite possible criticisms
of the animal model, glucocorticoid-induced osteoporosis might
be a fair representation of a common clinical situation.
CONCLUSION
There are advantages and disadvantages of every animal
model which involves artificial induction of a compromised
metabolic state. However, the induction of an osteopenic state
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in the minipig by oral administration of glucocorticoids is
predictable, and is minimally invasive when compared to surgical
ovariectomy. In summary, the induction of osteoporosis in the
minipig appears to be a promising model for the evaluation of the
osseointegration of dental implants under systemically impaired
osseous conditions.
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